These ligands are therefore promising candidates for the development of β-blockers devoid of β2-AR–mediated adverse effects of bronchospasm and vasoconstriction and, thus, may prove beneficial in patients with concomitant cardiovascular and respiratory disease or limb ischemia (peripheral vascular disease). The gene discussed is ADRB2; the disease is limb ischemia.